ArticleBlood2021
IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM.
Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Detailed immunophenotypic and genetic characterization of bone marrow clonal plasma cells and B-cells in early-stage monoclonal gammopathies.Blood cancer journal · 2026Article
- Review
- Successful Salvage Therapy with Pomalidomide, Cyclophosphamide, and Dexamethasone for IgM Myeloma with t (11;14) and Dim CD38 Expression Refractory to Daratumumab, Lenalidomide, and Dexamethasone.Internal medicine (Tokyo, Japan) · 2025Article
- Article
- Review
- Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations.Blood advances · 2023Article
- Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.Nature medicine · 2023Article
- Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review.Frontiers in pharmacology · 2023Review
- IgM monoclonal gammopathies of clinical significance: diagnosis and management.Haematologica · 2022Review
- Multiple myeloma with t(11;14): unique biology and evolving landscape.American journal of cancer research · 2022Review
- Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges.Frontiers in oncology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
Immunoglobulin M (IgM) multiple myeloma (MM) is a rare disease subgroup. Its differentiation from other IgM-producing gammopathies such as Waldenström macroglobulinemia (WM) has not been well characterized but is essential for proper risk assessment and treatment. In this study, we investigated genomic and transcriptomic characteristics of IgM-MM samples using whole-genome and transcriptome sequencing to identify differentiating characteristics from non-IgM-MM and WM. Our results suggest that IgM-MM shares most of its defining structural variants and gene-expression profiling with MM, but has some key characteristics, including t(11;14) translocation, chromosome 6 and 13 deletion as well as distinct molecular and transcription-factor signatures. Furthermore, IgM-MM translocations were predominantly characterized by VHDHJH recombination-induced breakpoints, as opposed to the usual class-switching region breakpoints; coupled with its lack of class switching, these data favor a pre-germinal center origin. Finally, we found elevated expression of clinically relevant targets, including CD20 and Bruton tyrosine kinase, as well as high BCL2/BCL2L1 ratio in IgM-MM, providing potential for targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.